A-Med Health Care has sold its Specialty Pharmacy Division to Altamont Capital Partners
July 2012 — A-Med Health Care has sold its Specialty Pharmacy Division to Altamont Capital Partners (ACP) for an undisclosed consideration.
Specialty Pharmacy Division is A-Med's specialty pharmacy division providing healthcare distribution services for patients with chronic diseases through home delivery.
Altamont Capital Partners is a private equity firm based in the San Francisco Bay area with over US$1 billion in capital, focused on investing in change-intensive middle market businesses. They are particularly drawn to companies which are constrained for some reason from realizing their full potential, and they seek opportunities to work in partnership with management to implement strategic and operational change. ACP is a generalist firm with deep experience in several verticals including business services, financial services, industrials, healthcare, technology, consumer, retail and aerospace & defense sectors.
A-Med Health Care provides healthcare distribution services for patients with chronic diseases through home delivery. A-Med's mission is to provide excellent care and achieve positive outcomes for its clients through comprehensive, cost effective, and quality services. Enhancing the health and well being of its clients promotes wellness. Utilization of available resources, consumer surveys, staff involvement, state and federal regulations, recognition of community and industry needs, technology, education, self evaluation, leadership, and financial stability will promote this mission.
Our role in the transaction
Oaklins' team in Los Angeles advised the seller. This transaction was for the specialty pharmacy component of the business only. This transaction was for the specialty pharmacy component of the business only.
Talk to the deal team
Gary Rabishaw
Oaklins Intrepid
Eduard Bagdasarian
Oaklins Intrepid
Jeremiah Mann
Oaklins Intrepid
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreCibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more